

## **New partnership launches Australian-first resource to support patients living with obesity and new home of *Don't Rush to Crush***

- **Therapeutic Guidelines** and **Advanced Pharmacy Australia** announce a strategic partnership to deliver accessible clinical resources to Australian healthcare professionals.
- The partnership welcomes the launch of *ObesiD*, a new digital resource, and the upcoming launch of a redesigned and improved *Don't Rush to Crush*.

**Tuesday 10 March 2026:** Key clinical resources for Australian healthcare professionals are set to become more accessible following the announcement of a partnership between **Therapeutic Guidelines** and **Advanced Pharmacy Australia (AdPha)**. The partnership will promote the quality use of medicines by enhancing access to trusted, evidence-based clinical resources that support decision making at the point of care, including *Don't Rush to Crush*, Australia's long-standing trusted guide to safely administering oral medicines to people with enteral feeding tubes or swallowing difficulties, and *ObesiD*, an industry-first resource designed to enhance care for patients with obesity.

An Australian-first, *ObesiD* will provide concise evidence-based advice on more than 70 medicines and guidance on dosage adjustment principles to support use of medicines in patients with obesity. With approximately one-third of Australian adults living with obesity, and a further 30% being overweight, the dedicated guide is essential to equip healthcare professionals with evidence-based strategies to tailor patient treatment.<sup>1</sup>

In line with Australia's broader digital healthcare transition, *ObesiD* will be accessible through a dedicated web and mobile app, with features including an integrated body weight calculator. The advanced digital experience is designed to support health professionals in delivering confident patient care. *ObesiD* will be available on **Therapeutic Guidelines** platforms 16 March 2026. Users with access to *Therapeutic Guidelines* will now be able to seamlessly switch between products.

Included in the Pharmacy Board of Australia's list of essential references for pharmacy practice, the new *Don't Rush to Crush* web app includes information on more than 600 oral medicines available in Australia. The point of care resource is set to become more widely accessible with a dedicated product app, enhanced user-centric design and upgraded search. This will be available on **Therapeutic Guidelines** platforms from 23 March 2026.

Trusted by clinicians for 15 years, *Don't Rush to Crush* is researched, reviewed and consistently updated by multidisciplinary experts for Australian practice, and in recent years has expanded through Australia-first dispersion testing, Australia-first oral liquid thickness testing and in response to medicines shortages.

Maintaining their commitment to promote the quality use of medicines, **Therapeutic Guidelines** will introduce additional guidelines throughout 2026. The *Kidney and Urinary guidelines* and *Sleep Disorders guidelines* will further support practitioners in delivering optimal care. Updates to the *Antibiotic guidelines* will also be published, building on the extensive 2025 update.

**Therapeutic Guidelines CEO, Dr Leigh-Anne Claase**, welcomed the collaboration.

“This partnership represents an exciting and innovative step forward in Australian health publishing. By working closely with AdPha, we can bring vital guidance to even more health professionals nationwide. We will continue to provide resources that are not only reliable and evidence based, but also more accessible and user friendly for the Australian healthcare community.” said Dr Claase.

**AdPha Chief Executive Kristin Michaels** emphasised the importance of safeguarding Australian expertise to uphold the care of Australia patients.

“We are so pleased to be working with Therapeutic Guidelines, combining our expertise to develop resources that meet the unique needs of Australian healthcare professionals and their patients,” Ms Michaels said. “As our population ages and more people take more medicines, there is only one *Don’t Rush to Crush: Australia’s* indispensable frontline resource when managing risk and ensuring quality care for patients with enteral feeding tubes or swallowing difficulties, in all healthcare settings.”

Through this partnership, **Therapeutic Guidelines** and **Advanced Pharmacy Australia** reaffirm their commitment to creating reliable, independent and evidence-based Australian clinical resources, now and into the future.

----- ENDS -----

**For further information or to arrange an interview, please contact:**

Lucy Byrne	Maitreyi Kulkarni
Palin Communications	Palin Communications
0400 843 389	0413 712 977
<a href="mailto:lucy@palin.com.au">lucy@palin.com.au</a>	<a href="mailto:maitreyi@palin.com.au">maitreyi@palin.com.au</a>

### **About Therapeutic Guidelines**

Therapeutic Guidelines is Australia’s leading digital healthcare publisher. For almost 50 years the Australian healthcare community has relied on Therapeutic Guidelines to provide an independent, evidence-based clinical resource. In the decades following the first Antibiotic

guidelines release, we grew rapidly and became Australia's leading not-for-profit healthcare publisher respected by clinicians at every stage of their career.

### **About Advanced Pharmacy Australia.**

Advanced Pharmacy Australia (AdPha) is the peak body committed to enriching patient care by extending advanced pharmacy from hospitals to everywhere medicines are needed. AdPha are an inclusive member organisation supporting pharmacy professionals working across hospitals and health services, to realise their full potential and meet the increasing needs of patients through evidence-based care.

### **About ObesiD**

ObesiD is a collaborative initiative by members of Advanced Pharmacy Australia with extensive expertise in managing drug dosing decisions in clinical practice. ObesiD shares the collective knowledge and clinical experience of its contributors, pharmacists and prescribers, while progressively expanding both the evidence base and the scope of its monographs.

ObesiD is an Australian-first clinical resource developed to support the care of patients living with obesity. It provides concise guidance on the principles of dosing in obesity, evidence-based recommendations for more than 70 medicines, integrated calculators, and a contemporary digital app experience designed for use in clinical practice.

### **About Don't Rush to Crush**

First published in 2011, Advanced Pharmacy Australia's *Don't Rush to Crush* is Australia's essential guide to safely administering oral medicines to people with enteral feeding tubes or swallowing difficulties, included in the Pharmacy Board of Australia's list of essential references for pharmacy practice.

*Don't Rush to Crush* includes comprehensive information on more than 600 oral medicines available in Australia, with 160 medicines subjected to dispersion testing of tablets and capsules, and information on oral liquids and thickness testing, and gastrointestinal dysfunction.

### **References:**

1. Australian Institute of Health and Welfare. Overweight and obesity. Canberra: Australian Institute of Health and Welfare; 2024. Available at: <https://www.aihw.gov.au/reports/overweight-obesity/overweight-and-obesity/contents/summary>